<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03185065</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00119702</org_study_id>
    <nct_id>NCT03185065</nct_id>
  </id_info>
  <brief_title>Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis</brief_title>
  <acronym>TRIUMPHANT-MS</acronym>
  <official_title>Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind (participants&#xD;
      and investigators), multicenter trial of 3 commonly used medications for treatment of&#xD;
      MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued&#xD;
      subjects with MS defined by McDonald Criteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind&#xD;
      (participants and investigators), multicenter trial of 3 commonly used medications for&#xD;
      treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in&#xD;
      fatigued subjects with MS defined by McDonald Criteria.&#xD;
&#xD;
      Using a balanced Latin-square crossover design, subjects will be allocated, in a&#xD;
      double-blind, randomized fashion, to one of the four treatment sequences (Figure 1): 1)&#xD;
      amantadine, placebo, modafinil, methylphenidate; 2) placebo, methylphenidate, amantadine,&#xD;
      modafinil; 3) modafinil, amantadine, methylphenidate, placebo; and 4) methylphenidate,&#xD;
      modafinil, placebo and amantadine. Each medication will be titrated over four weeks to the&#xD;
      participants' highest tolerated dose or the pre-defined highest dose. The dosing and&#xD;
      titration schedule of the study medications are depicted in Figure 2. Each treatment period&#xD;
      will be 6 weeks and there will be a 2-week washout period between each treatment period. At&#xD;
      the beginning of the trial, a biostatistician at University of California, San Francisco&#xD;
      (UCSF) will prepare a concealed allocation schedule, randomly assigning the four sequences,&#xD;
      in blocks of 4, to a consecutive series of numbers and at the time of enrollment, each&#xD;
      participant will be assigned the next consecutive number (and hence the sequence of study&#xD;
      medications).&#xD;
&#xD;
      The primary endpoint of the study will be fatigue severity as measured by the MFIS score,&#xD;
      between 26th and 35th day of each treatment period (while the patient is taking the maximal&#xD;
      tolerated or target dose). The MFIS is a validated patient-reported outcome. The&#xD;
      questionnaire will be administered remotely (through internet, phone or mailed forms) and the&#xD;
      participants can answer the questions in few minutes while at home or at their work place.&#xD;
      The questionnaire has been validated in English and Spanish.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 4, 2017</start_date>
  <completion_date type="Actual">November 21, 2019</completion_date>
  <primary_completion_date type="Actual">November 21, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind, multicenter trial of 3 commonly used medications for treatment of Multiple Sclerosis related fatigue versus placebo in fatigued subjects with MS.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Fatigue Impact Scale (MFIS) Score</measure>
    <time_frame>Week 5 of each treatment period</time_frame>
    <description>MFIS score during the fifth week of treatment period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life in Neurological Disorders (Neuro-QoL) Item Bank - Fatigue Score</measure>
    <time_frame>Week 5 of each treatment period</time_frame>
    <description>Neuro-QoL Item Bank - Fatigue T score during the fifth week of treatment period. T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale (ESS) Score</measure>
    <time_frame>Week 5 of each treatment period</time_frame>
    <description>ESS score during the fifth week of treatment period. The ESS score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Fatigue in Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>amantadine, placebo, modafinil, methylphenidate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo, methylphenidate, amantadine, modafinil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modafinil, amantadine, methylphenidate, placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methylphenidate, modafinil, placebo and amantadine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine</intervention_name>
    <description>100 mg of amantadine increased to 200 mg of amantadine, if tolerated</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>100 mg of modafinil increased to 200 mg of modafinil, if tolerated</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>1 placebo capsule increased to max of 2 capsules twice daily</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age 18 years and older.&#xD;
&#xD;
          -  Females of childbearing age must have a negative urine pregnancy test at baseline and&#xD;
             use an effective method of contraception during the study.&#xD;
&#xD;
          -  Diagnosis of MS (according to the 2010 McDonald criteria).&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) score at the time of screening 0.0-7.0.&#xD;
&#xD;
          -  Fatigue reportedly present and screening Modified Fatigue Impact Scale (MFIS) score&#xD;
             more than 33.&#xD;
&#xD;
          -  At least a two-week washout for any fatigue-related drug, including study medications.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Neurodegenerative disorders other than relapsing or progressive MS.&#xD;
&#xD;
          -  Breastfeeding or pregnant.&#xD;
&#xD;
          -  History of coronary artery disease or congestive heart failure.&#xD;
&#xD;
          -  Uncontrolled hypertension at screening (history of high blood pressure and screening&#xD;
             systolic blood pressure &gt;160 or diastolic blood pressure&gt;100).&#xD;
&#xD;
          -  Glomerular Filtration Rate (GFR) (glomerular filtration rate) &lt; 50.&#xD;
&#xD;
          -  Abnormal liver function at screening (AST or Alanine Aminotransferase (ALT) more than&#xD;
             twice the upper limit of normal).&#xD;
&#xD;
          -  Terminal medical conditions.&#xD;
&#xD;
          -  Currently treated for active malignancy.&#xD;
&#xD;
          -  Planned surgery or move within 8 months of screening.&#xD;
&#xD;
          -  Alcohol or substance abuse in the past year (except marijuana or other cannabinoids).&#xD;
&#xD;
          -  A history of intolerance or allergic or anaphylactic reaction to amantadine,&#xD;
             modafinil, methylphenidate or any component of the preparation.&#xD;
&#xD;
          -  Clinically unstable medical or psychiatric disorders that require acute treatment as&#xD;
             determined by the PI.&#xD;
&#xD;
          -  Concurrent use of monoamine oxidase inhibitors-B.&#xD;
&#xD;
          -  Hypersensitivity/idiosyncrasy to sympathomimetic amines&#xD;
&#xD;
          -  Inability to communicate or answer the questionnaires in English or Spanish.&#xD;
&#xD;
          -  Severe untreated anemia (blood hemoglobin &lt;9gr/dl)&#xD;
&#xD;
          -  History of untreated hypothyroidism&#xD;
&#xD;
          -  History of untreated sleep apnea&#xD;
&#xD;
          -  History of long QT syndrome, atrial fibrillation or tachyarrhythmias (other than sinus&#xD;
             tachycardia)&#xD;
&#xD;
          -  History of ischemic or hemorrhagic stroke&#xD;
&#xD;
          -  History of glaucoma&#xD;
&#xD;
          -  History of Tourette syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bardia Nourbakhsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <results_first_submitted>September 24, 2020</results_first_submitted>
  <results_first_submitted_qc>September 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2020</results_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03185065/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A</title>
          <description>amantadine, placebo, modafinil, methylphenidate&#xD;
Amantadine: 100 mg of amantadine increased to 200 mg of amantadine, if tolerated&#xD;
Modafinil: 100 mg of modafinil increased to 200 mg of modafinil, if tolerated&#xD;
Methylphenidate: 5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated&#xD;
Placebos: 1 placebo capsule increased to max of 2 capsules twice daily</description>
        </group>
        <group group_id="P2">
          <title>Arm B</title>
          <description>placebo, methylphenidate, amantadine, modafinil&#xD;
Amantadine: 100 mg of amantadine increased to 200 mg of amantadine, if tolerated&#xD;
Modafinil: 100 mg of modafinil increased to 200 mg of modafinil, if tolerated&#xD;
Methylphenidate: 5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated&#xD;
Placebos: 1 placebo capsule increased to max of 2 capsules twice daily</description>
        </group>
        <group group_id="P3">
          <title>Arm C</title>
          <description>modafinil, amantadine, methylphenidate, placebo&#xD;
Amantadine: 100 mg of amantadine increased to 200 mg of amantadine, if tolerated&#xD;
Modafinil: 100 mg of modafinil increased to 200 mg of modafinil, if tolerated&#xD;
Methylphenidate: 5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated&#xD;
Placebos: 1 placebo capsule increased to max of 2 capsules twice daily</description>
        </group>
        <group group_id="P4">
          <title>Arm D</title>
          <description>methylphenidate, modafinil, placebo and amantadine&#xD;
Amantadine: 100 mg of amantadine increased to 200 mg of amantadine, if tolerated&#xD;
Modafinil: 100 mg of modafinil increased to 200 mg of modafinil, if tolerated&#xD;
Methylphenidate: 5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated&#xD;
Placebos: 1 placebo capsule increased to max of 2 capsules twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2 (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3 (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4 (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A</title>
          <description>amantadine, placebo, modafinil, methylphenidate&#xD;
Amantadine: 100 mg of amantadine increased to 200 mg of amantadine, if tolerated&#xD;
Modafinil: 100 mg of modafinil increased to 200 mg of modafinil, if tolerated&#xD;
Methylphenidate: 5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated&#xD;
Placebos: 1 placebo capsule increased to max of 2 capsules twice daily</description>
        </group>
        <group group_id="B2">
          <title>Arm B</title>
          <description>placebo, methylphenidate, amantadine, modafinil&#xD;
Amantadine: 100 mg of amantadine increased to 200 mg of amantadine, if tolerated&#xD;
Modafinil: 100 mg of modafinil increased to 200 mg of modafinil, if tolerated&#xD;
Methylphenidate: 5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated&#xD;
Placebos: 1 placebo capsule increased to max of 2 capsules twice daily</description>
        </group>
        <group group_id="B3">
          <title>Arm C</title>
          <description>modafinil, amantadine, methylphenidate, placebo&#xD;
Amantadine: 100 mg of amantadine increased to 200 mg of amantadine, if tolerated&#xD;
Modafinil: 100 mg of modafinil increased to 200 mg of modafinil, if tolerated&#xD;
Methylphenidate: 5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated&#xD;
Placebos: 1 placebo capsule increased to max of 2 capsules twice daily</description>
        </group>
        <group group_id="B4">
          <title>Arm D</title>
          <description>methylphenidate, modafinil, placebo and amantadine&#xD;
Amantadine: 100 mg of amantadine increased to 200 mg of amantadine, if tolerated&#xD;
Modafinil: 100 mg of modafinil increased to 200 mg of modafinil, if tolerated&#xD;
Methylphenidate: 5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated&#xD;
Placebos: 1 placebo capsule increased to max of 2 capsules twice daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="37"/>
            <count group_id="B5" value="141"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.3" spread="9.9"/>
                    <measurement group_id="B2" value="46.9" spread="12.4"/>
                    <measurement group_id="B3" value="46.1" spread="10.3"/>
                    <measurement group_id="B4" value="45.8" spread="10.2"/>
                    <measurement group_id="B5" value="46.8" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Modified Fatigue Impact Scale (MFIS) Score</title>
        <description>MFIS score during the fifth week of treatment period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue.</description>
        <time_frame>Week 5 of each treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo capsule increased to max of 2 capsules twice daily</description>
          </group>
          <group group_id="O2">
            <title>Amantadine</title>
            <description>100 mg of amantadine increased to 200 mg of amantadine, if tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Modafinil</title>
            <description>100 mg of modafinil increased to 200 mg of modafinil, if tolerated.</description>
          </group>
          <group group_id="O4">
            <title>Methylphenidate</title>
            <description>5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Fatigue Impact Scale (MFIS) Score</title>
          <description>MFIS score during the fifth week of treatment period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" lower_limit="38.2" upper_limit="43.1"/>
                    <measurement group_id="O2" value="41.3" lower_limit="38.8" upper_limit="43.7"/>
                    <measurement group_id="O3" value="39.0" lower_limit="36.6" upper_limit="41.4"/>
                    <measurement group_id="O4" value="38.6" lower_limit="36.2" upper_limit="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life in Neurological Disorders (Neuro-QoL) Item Bank - Fatigue Score</title>
        <description>Neuro-QoL Item Bank - Fatigue T score during the fifth week of treatment period. T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue.</description>
        <time_frame>Week 5 of each treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo capsule increased to max of 2 capsules twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Amantadine</title>
            <description>100 mg of amantadine increased to 200 mg of amantadine, if tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Modafinil</title>
            <description>100 mg of modafinil increased to 200 mg of modafinil, if tolerated.</description>
          </group>
          <group group_id="O4">
            <title>Methylphenidate</title>
            <description>5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life in Neurological Disorders (Neuro-QoL) Item Bank - Fatigue Score</title>
          <description>Neuro-QoL Item Bank - Fatigue T score during the fifth week of treatment period. T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1" lower_limit="51.9" upper_limit="54.3"/>
                    <measurement group_id="O2" value="53.0" lower_limit="51.7" upper_limit="54.2"/>
                    <measurement group_id="O3" value="52.5" lower_limit="51.3" upper_limit="53.8"/>
                    <measurement group_id="O4" value="52.0" lower_limit="50.8" upper_limit="53.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epworth Sleepiness Scale (ESS) Score</title>
        <description>ESS score during the fifth week of treatment period. The ESS score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'.</description>
        <time_frame>Week 5 of each treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo capsule increased to max of 2 capsules twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Amantadine</title>
            <description>100 mg of amantadine increased to 200 mg of amantadine, if tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Modafinil</title>
            <description>100 mg of modafinil increased to 200 mg of modafinil, if tolerated.</description>
          </group>
          <group group_id="O4">
            <title>Methylphenidate</title>
            <description>5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Epworth Sleepiness Scale (ESS) Score</title>
          <description>ESS score during the fifth week of treatment period. The ESS score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="8.7" upper_limit="10.1"/>
                    <measurement group_id="O2" value="9.3" lower_limit="8.6" upper_limit="10.1"/>
                    <measurement group_id="O3" value="8.3" lower_limit="7.6" upper_limit="9.1"/>
                    <measurement group_id="O4" value="8.8" lower_limit="8.1" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Acceptability of Treatment as Assessed by a Single Question Questionnaire</title>
        <description>Participants will answer yes or no to this question: &quot;Taken into consideration the possible benefits and/or disadvantages of this medication, would you choose it, going forward to treat your MS fatigue?&quot;. The number of participants who answered &quot;Yes&quot; to this question is reported here.</description>
        <time_frame>Week 5 of each treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>1 placebo capsule increased to max of 2 capsules twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Amantadine</title>
            <description>100 mg of amantadine increased to 200 mg of amantadine, if tolerated.</description>
          </group>
          <group group_id="O3">
            <title>Modafinil</title>
            <description>100 mg of modafinil increased to 200 mg of modafinil, if tolerated.</description>
          </group>
          <group group_id="O4">
            <title>Methylphenidate</title>
            <description>5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptability of Treatment as Assessed by a Single Question Questionnaire</title>
          <description>Participants will answer yes or no to this question: &quot;Taken into consideration the possible benefits and/or disadvantages of this medication, would you choose it, going forward to treat your MS fatigue?&quot;. The number of participants who answered &quot;Yes&quot; to this question is reported here.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
                <count group_id="O4" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during each six-week medication period.</time_frame>
      <desc>The numbers in the adverse event section are patients who constitute the safety dataset. These are patients who at least took one dose of that medication (whether or not they had their efficacy measured).</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>1 placebo capsule increased to max of 2 capsules twice daily.</description>
        </group>
        <group group_id="E2">
          <title>Amantadine</title>
          <description>100 mg of amantadine increased to 200 mg of amantadine, if tolerated.</description>
        </group>
        <group group_id="E3">
          <title>Modafinil</title>
          <description>100 mg of modafinil increased to 200 mg of modafinil, if tolerated.</description>
        </group>
        <group group_id="E4">
          <title>Methylphenidate</title>
          <description>5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardiitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>MS exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning, and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="129"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bardia Nourbakhsh</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>4106141522</phone>
      <email>bnourba1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

